Drugs / HS-20124
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06763159 | Oct 2024 → Dec 2026 expected | — | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20124 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06763159 ↗ |
| Route | Intravenous | “HS-20124 for IV infusion of various dose strengths administered in 21 day dosing cycles” NCT06763159 ↗ |
| Target | CDH6 | “HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6.” NCT06763159 ↗ |